Redefining the Treatment of Autoimmune, Infectious and Metabolic Diseases
ImmuPharma PLC (LSE: IMM) is a clinical-stage biopharmaceutical company developing innovative peptide-based therapeutics and precision diagnostics designed to transform the treatment of autoimmune diseases, infectious diseases, and metabolic disorders. Our ambition is clear:
to move beyond symptom control and develop therapies capable of delivering durable remission — and ultimately curative outcomes.
Share Price
A Clear Strategic Vision
The current standard of care in autoimmune disease primarily focuses on controlling inflammation rather than addressing its root cause. ImmuPharma is pioneering a new therapeutic paradigm through its proprietary platforms:
- Restoring immune tolerance instead of broad suppression
- Identifying and targeting the right patients through companion diagnostics
- Expanding peptide innovation into metabolic disease with Kapiglucagon, a novel therapeutic approach targeting key metabolic pathways
- Building a precision medicine ecosystem that enables durable remission and improved long-term outcomes
This differentiated strategy positions ImmuPharma at the intersection of immunology, precision medicine, and peptide-based therapeutics, areas driving the next wave of biomedical innovation.
A Differentiated Pipeline with Global Potential
ImmuPharma’s portfolio is built around three complementary pillars: autoimmunity, anti-infectives, and metabolic disease — creating multiple value drivers.
- P140 (Lupuzor™): A first-in-class immune normalizer designed to correct underlying immune dysregulation while preserving normal immune function. The platform has potential across multiple autoimmune diseases.
- Type M Diagnostic Platform: A next-generation companion diagnostic designed to identify “super-responder” patients across major autoimmune indications, enabling a precision medicine approach and improving clinical outcomes.
- Kapiglucagon: A novel peptide-based therapeutic candidate targeting metabolic pathways involved in energy regulation and metabolic diseases, expanding ImmuPharma’s platform into high-growth areas of metabolic medicine.
- Anti-infectives (BioAMB & BioCIN): Next-generation therapies designed to address the growing global threat of antimicrobial resistance in severe fungal and bacterial infections.
Together, these programs position ImmuPharma to address major unmet medical needs across multiple high-value therapeutic areas. This diversified pipeline positions ImmuPharma to deliver multiple development and partnering opportunities.
Strategic Partnerships and IP Strength
- Robust patent estate.
- A scalable peptide-based platform with multiple partnering opportunities across therapeutic areas.
Why Invest in ImmuPharma?
- A unique curative vision in autoimmune diseases, moving beyond conventional immunosuppression.
- First-in-class therapeutic and diagnostic platforms enabling precision medicine.
- Multiple value drivers across autoimmune, infectious, and metabolic diseases.
- Clinical assets and near-term development catalysts, including P140 and emerging platform applications.
- Strong intellectual property protection and strategic partnerships supporting long-term growth.
Creating Sustainable Value
ImmuPharma is entering a new phase of growth, leveraging its scientific leadership, proprietary peptide platforms, and strategic partnerships to unlock significant value for patients and shareholders.
We’re not just developing new drugs — we’re redefining how autoimmune, infectious, and metabolic diseases can be treated.
Professional advisers
Nominated Adviser ‘NOMAD’
SPARK Advisory Partners Limited
5 St. John’s Lane
London
EC1M 4BH
www.sparkadvisorypartners.com
Joint Broker
Stanford Capital Partners Limited
5-7 Cranwood Street
London
EC1V 9EE
www.stanfordcp.co.uk/contact-us
Joint Broker
Si Capital Limited
46 Bridge St
Godalming
GU7 1HL
info@sicapital.co.uk
Public Relations & Investor Relations
lisa.baderoon@immupharma.com
Principal Bankers
Royal Bank of Scotland plc
62/63 Threadneedle Street
London
EC2R 8LA
www.rbs.co.uk
Auditors
Crowe LLP
55 Ludgate Hill
London
EC4M 7JW
www.crowe.com/uk
Legal Representatives
Broadfield UK
One Bartholomew Close
London
EC1A 7BL
www.broadfield-law.com
Patent Agents
Haseltine Lake Kempner LLP
7th Floor, Cheapside House
138 Cheapside
London
EC2V 6BJ
www.hlk-ip.com
Registrars
Computershare Investor Services PLC
PO Box 82 The Pavilions
Bridgewater Road
Bristol
BS99 7NH
www.computershare.com